Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML
Open Access
- 1 August 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (15) , 2307-2311
Abstract
Key Points DNMT3AR882, TET2, ASXL1, and SRSF2 mutations identified at the time of diagnosis are associated with delayed count recovery. Persistence of preleukemic mutations in remission at high variant allele frequency is associated with delayed count recovery.Keywords
This publication has 19 references indexed in Scilit:
- Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaLeukemia, 2018
- The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemiaPLOS ONE, 2017
- Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2016
- Detecting ultralow-frequency mutations by Duplex SequencingNature Protocols, 2014
- Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high‐grade myelodysplastic syndromesAmerican Journal of Hematology, 2014
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in miceProceedings of the National Academy of Sciences, 2011
- Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.2000
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966
- The Quantitative Relation between Platelet Count and Hemorrhage in Patients with Acute LeukemiaNew England Journal of Medicine, 1962